title: Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
abstract: BACKGROUND
  Booster vaccination with the combined Haemophilus influenza type b-Neisseria meningitides serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) has been reported to induce different MenC antibody responses depending on the priming vaccines, with a possible impact on long-term protection. Here, the five-year persistence of immune responses induced by a booster dose of Hib-MenC-TT was evaluated in toddlers primed with either Hib-MenC-TT or MenC-TT.
  
  
  METHODS
  This is the follow-up of a phase III, open, randomized study, in which a Hib-MenC-TT booster dose was given at 13.14 months of age to toddlers primed with either 3 doses of Hib-MenC-TT or 2 doses of MenC-TT in infancy. Children in the control group had received 3 primary doses and a booster dose of MenC-CRM197. Functional antibodies against MenC were measured by a serum bactericidal assay with rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate by enzyme-linked immunosorbent assay. Serious adverse events considered by the investigator to be possibly related to vaccination were to be reported throughout the study.
  
  
  RESULTS
  At 66 months postbooster, rSBA-MenC titers ≥8 were retained by 82.6% of children primed with Hib-MenC-TT, 94.1% of children primed with MenC-TT, and 60.9% of children in the control group. All children who received the Hib-MenC-TT booster dose retained anti- polyribosylribitol phosphate concentrations ≥0.15 μg/mL. No serious adverse events considered possibly related to vaccination were reported.
  
  
  CONCLUSIONS
  There is evidence of good antibody persistence against MenC and Hib for more than five years postbooster vaccination with Hib-MenC TT in toddlers primed with Hib-MenC-TT or MenC-TT.
authors: Hospital Universitario de Móstoles, Madrid, Spain. juanctejedor@telefonica.net
authors: Juan Carlos
authors: JC
authors: Tejedor
authors: José Manuel
authors: JM
authors: Merino
authors: Manuel
authors: M
authors: Moro
authors: Maria-Luisa
authors: ML
authors: Navarro
authors: José
authors: J
authors: Espín
authors: Félix
authors: F
authors: Omeñaca
authors: José
authors: J
authors: García-Sicilia
authors: David
authors: D
authors: Moreno-Pérez
authors: Jesús
authors: J
authors: Ruiz-Contreras
authors: Fernando
authors: F
authors: Centeno
authors: Francisco
authors: F
authors: Barrio
authors: Lucia
authors: L
authors: Cabanillas
authors: Marta
authors: M
authors: Muro
authors: Carlos
authors: C
authors: Esporrin
authors: Maria Jose
authors: MJ
authors: De Torres
authors: Magalie
authors: M
authors: Caubet
authors: Dominique
authors: D
authors: Boutriau
authors: Jacqueline M
authors: JM
authors: Miller
authors: Narcisa
authors: N
authors: Mesaros
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D001770:Blood Bactericidal Activity; D002648:Child; D002675:Child, Preschool; D003165:Complement System Proteins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects / Q000379:methods*; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D013997:Time Factors; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; D022401:Meningococcal Vaccines; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; D003165:Complement System Proteins